Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’

Autor: Grössmann, N., Wolf, S., Rothschedl, E., Wild, C.

Publikováno v: In ESMO Open June 2021 6(3)

Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit

Autor: Grössmann, N., Del Paggio, J.C., Wolf, S., Sullivan, R., Booth, C.M., Rosian, K., Emprechtinger, R., Wild, C.

Publikováno v: In European Journal of Cancer September 2017 82:66-71

Published evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015

Autor: Grössmann, N, Robausch, M, Rothschedl, E, Wild, C, Simon, J

Publikováno v: Nützliche patientenrelevante Forschung; 21. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin; 20200213-20200215; Basel, Schweiz; DOC20ebmS2-V1-01 /20200212/

Background/research question: Health-related quality of life (HRQoL) is one of the most important patient-relevant study endpoints for the direct measurement of the benefit of cancer drugs. Therefore, our aim was to detect cancer drugs with no publis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee05e702bc6b5c14c9ce54a556b42aa

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Utilisation of the ESMO-MCBS in practice of HTA

Autor: Wild, C., Grössmann, N., Bonanno, P.V., Bucsics, A., Furst, J., Garuoliene, K., Godman, B., Gulbinovič, J., Jones, J., Pomorski, M.K., Emprechtinger, R.

Publikováno v: In Annals of Oncology November 2016 27(11):2134-2136